IMPEDIMED TECHNOLOGY BACKED BY NEW STUDY

A STUDY has found that Brisbane-based company ImpediMed's (ASX: IPD) L-Dex technology (pictured) is effective in monitoring patients that are at-risk of breast cancer related lymphoedema.

The study, conducted in the United States and published in the journal Frontiers in Oncology, reported that 326 patients were monitored with the L-Dex technology  post axillary lymph node dissection (ALND) or sentinel lymph node biopsy (SLNB).

Through monitoring fluid status and body composition through bioimpedance spectroscopy, L-Dex allowed for early intervention for patients who showed further incidence of sub-clinical lymphoedema after undergoing either an ALND or SLNB and allowed reduction in the persistence of this condition by 99.5 per cent for ALND patients and 91.4 per cent for SLNB patients.

The study concluded, "The results of this retrospective study demonstrate that L-Dex assessments can be incorporated into routine breast cancer programs as part of follow-up."

The researchers, from Texas, noted that this was critically important, given new health guidelines in the US for monitoring the post-treatment follow-up care of for breast cancer patients.

"As we await the results of the post-approval L-Dex study currently underway, we are pleased at the publication of these important and positive clinical data for L-Dex," says Richard Carreon, ImpediMed Managing Director and CEO in a statement to the ASX today.

L-Dex was developed by Associate Professor Leigh Ward from the University of Queensland.

IPD is trading up 6.55 per cent on the ASX this morning, at $3.94 per share.